Propolis Extract, Nanovitamin C and Nanovitamin E on Desquamative Gingivitis

Sponsor
Universidad Complutense de Madrid (Other)
Overall Status
Recruiting
CT.gov ID
NCT05124366
Collaborator
(none)
21
1
2
33.9
0.6

Study Details

Study Description

Brief Summary

Objective: To evaluate the effectiveness of a gel containing nanovitamin C, nanovitamin E and propolis extract compared to a placebo in the treatment of desquamative gingivitis (GD) in patients with mucocutaneous diseases with gingival involvement. The possible improvement in the quality of life of these patients after treatment will also be evaluated.

Study design: Double-blind, randomized controlled study.

Patients: GD patients are being selected from the Postgraduate 'Specialist in Oral Medicine' of the Faculty of Dentistry, Complutense University of Madrid.

Allocation: Patients are being randomly assigned to the study group (dental prophylaxis + oral hygiene instructions + use of propolis gel for 4 weeks) or to the placebo group (dental prophylaxis + oral hygiene instructions + use of placebo gel for 4 weeks ). Both the study gel and the placebo are being used for brushing their teeth and for application in areas with GD.

Variables: The severity of the GD will be collected according to the scale of Arduino et al. 2017 and the periodontal variables (plaque index, probing bleeding index and probing depth). Pain during treatment will be recorded using a 10 cm visual analog scale (VAS). The quality of life in relation to oral health will be recorded using the Oral Health Impact Profile-14 (OHIP-14) questionnaire. These variables will be collected on day 0, 2 and 4 weeks after using the study gel or placebo.

Condition or Disease Intervention/Treatment Phase
  • Procedure: dental prophylaxis + oral hygiene instructions
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
21 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Propolis Extract, Nanovitamin C and Nanovitamin E on Desquamative Gingivitis
Actual Study Start Date :
Sep 1, 2019
Actual Primary Completion Date :
Oct 16, 2021
Anticipated Study Completion Date :
Jun 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Study group

Nanovitamin E, nanovitamin C and propolis extract gel

Procedure: dental prophylaxis + oral hygiene instructions
Follow up: 2 weeks and 4 weeks

Placebo Comparator: Placebo

Gel without nanovitamin E, nanovitamin C and propolis extract

Procedure: dental prophylaxis + oral hygiene instructions
Follow up: 2 weeks and 4 weeks

Outcome Measures

Primary Outcome Measures

  1. The severity of the GD will be collected according to the scale of Arduino et al. 2017 [Baseline]

    The Scale collects a value for each sextant in vestibular and another value in lingual / palatal (12 in total, six times vestibular and six times lingual / palatal). The criteria for scoring are as follows: (0) no detectable gingival lesions present, (1) only white lesions, (2) mild erythema (<3mm from the gingival margins), (3) one or more blisters or erythema clinically obvious (> 3mm from the gingival margins), (4) erosion or ulcer. When there are different characteristics, the clinician should choose the highest index, so the total score can vary from 0 to 48. Higher results indicate a more serious clinical disease.

  2. The severity of the GD will be collected according to the scale of Arduino et al. 2017 [2 weeks]

    The Scale collects a value for each sextant in vestibular and another value in lingual / palatal (12 in total, six times vestibular and six times lingual / palatal). The criteria for scoring are as follows: (0) no detectable gingival lesions present, (1) only white lesions, (2) mild erythema (<3mm from the gingival margins), (3) one or more blisters or erythema clinically obvious (> 3mm from the gingival margins), (4) erosion or ulcer. When there are different characteristics, the clinician should choose the highest index, so the total score can vary from 0 to 48. Higher results indicate a more serious clinical disease.

  3. The severity of the GD will be collected according to the scale of Arduino et al. 2017 [4 weeks]

    The Scale collects a value for each sextant in vestibular and another value in lingual / palatal (12 in total, six times vestibular and six times lingual / palatal). The criteria for scoring are as follows: (0) no detectable gingival lesions present, (1) only white lesions, (2) mild erythema (<3mm from the gingival margins), (3) one or more blisters or erythema clinically obvious (> 3mm from the gingival margins), (4) erosion or ulcer. When there are different characteristics, the clinician should choose the highest index, so the total score can vary from 0 to 48. Higher results indicate a more serious clinical disease.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 100 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Patients over 18 years of age.

  2. Patients with a clinical and histological diagnosis of some mucocutaneous disease. Patients diagnosed with oral lichen planus will be selected according to the American Academy of Oral and Maxillofacial Pathology, pemphigus vulgaris and / or scarring pemphigoid according to the 2015 World Workshop on Oral Medicine.

  3. Patients who present GD, that is, erythema, epithelial desquamation, atrophy, painful erosions or ulceration of the free and / or attached gingiva, which is not related to the local accumulation of plaque.

Exclusion Criteria:
  1. Being in cancer treatment with head and neck radiotherapy, chemotherapy or immunotherapy.

  2. Being diabetic.

  3. Being on topical corticosteroid treatment in the previous 4 weeks or systemic treatment in the previous 8 weeks.

  4. Those patients who do not present the anterosuperior sector (from canine to upper canine) or the anteroinferior sector (from canine to lower canine) will also be excluded.

  5. Pregnant or breastfeeding.

  6. Being a smoker.

  7. Use of rinses for plaque control.

  8. Being medicated with drugs associated with gingival enlargement such as cyclosporine, calcium channel blockers and phenytoin.

  9. To have taken antibiotics and / or anti-inflammatories 3 months before the study.

  10. Taking medications capable of producing lichenoid reactions.

  11. Patients who do not want to sign the informed consent.

  12. Patients with periodontitis according to the consensus criteria of Papapanou et al. 2018 or patients treated for unstable periodontal disease according to the classification of Chapple et al. 2017.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Universidad Complutense de Madrid Madrid Spain 28005

Sponsors and Collaborators

  • Universidad Complutense de Madrid

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Rosa María López-Pintor Muñoz, Dos, PhD, Associate Professor., Universidad Complutense de Madrid
ClinicalTrials.gov Identifier:
NCT05124366
Other Study ID Numbers:
  • 0005
First Posted:
Nov 18, 2021
Last Update Posted:
Nov 18, 2021
Last Verified:
Nov 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Rosa María López-Pintor Muñoz, Dos, PhD, Associate Professor., Universidad Complutense de Madrid
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 18, 2021